Haloperidol hydrochloride, a potent dopamine D2 receptor antagonist, is an effective antipsychotic agent.

Administering 1 mg of Haloperidol intra-arterially reduces dopamine-induced pancreatic secretion. At a dosage of 3 mg, Haloperidol entirely nullifies the effect of 10 μg of dopamine on the pancreases of dogs [1]. Furthermore, Haloperidol (10 mg/kg) alongside chlorpromazine (CPZ, 15 mg/kg) mitigates mescaline-induced behavioral changes in mice within 7 to 10 minutes when administered 45 minutes following a 50 mg/kg (2 μc) dose of mescaline. However, Haloperidol does not influence the rate at which mescaline is eliminated [2].